fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Reata Pharmaceuticals closes CATALYST study of bardoxolone methyl for connective tissue disease-associated pulmonary arterial hypertension .

Written by | 6 Apr 2020

Reata Pharmaceuticals, Inc. provided an update on the impact of the COVID-19 pandemic on its clinical programs , drug supply chain, and business operations. The Company announced measures… read more.

Case study in Wuhan, China shows positive effect of Actemra as a treatment for COVID-19 and is published in Blood Advances.- Roche

Written by | 5 Apr 2020

A case study of a patient in Wuhan, China, suggests that the immunosuppressant Actemra (tocilizumab) from Roche may be an effective COVID-19 treatment for very ill patients who… read more.

FDA grants emergency use authorization for new COVID-19 diagnostic for use in U.S- BD + BioGX Inc.

Written by | 4 Apr 2020

-BD (Becton, Dickinson and Company) , a leading global medical technology company, and BioGX Inc., a molecular diagnostics company, announced that the FDA has granted Emergency Use Authorization… read more.

Vanda Pharma initiates ODYSSEY VLY-686-3501 trial of tradipitant in hospitalized patients with COVID-19.

Written by | 4 Apr 2020

Vanda Pharmaceuticals Inc. announced the initiation of clinical study, ODYSSEY VLY-686-3501, in hospitalized patients with COVID-19. The novel SARS-CoV-2 coronavirus is associated with a lower respiratory tract inflammation… read more.

FDA grants emergency use authorization for new COVID-19 diagnostic for use in U.S- BD + BioGX Inc.

Written by | 4 Apr 2020

-BD (Becton, Dickinson and Company) , a leading global medical technology company, and BioGX Inc., a molecular diagnostics company, announced that the FDA has granted Emergency Use Authorization… read more.

Novartis initiates clinical study of Jakavi in severe COVID-19 patients and establishes international compassionate use program. – Novartis + Incyte Corpn.

Written by | 3 Apr 2020

Novartis announced plans to initiate a Phase III clinical trial in collaboration with Incyte to evaluate the use of Jakavi (ruxolitinib) for treatment of a type of severe… read more.

Chembio Diagnostics launches rapid DPP COVID-19 serological point-of-care test to determine exposure to the COVID-19 virus.

Written by | 3 Apr 2020

Chembio Diagnostics, Inc. a leading point-of-care diagnostic company focused on infectious diseases, announced the US launch of the rapid DPP COVID-19 serological point-of-care test for the detection of… read more.

interima analysis of phase III Atalante 1 trial of Tedopi meets endpoint in NSCLC but trial on temporary hold.- OSE Immunotherapeutics

Written by | 2 Apr 2020

OSE Immunotherapeutics announced that the primary endpoint was met in the predefined Step-1 analysis of its Phase III Atalante 1 clinical trial of Tedopi (T-lymphocyte stimulators) in HLA-A2… read more.

Mallinckrodt and Novoteris receive clearance from Health Canada to start a pilot trial of high-dose inhaled nitric oxide therapy for COVID-19 infection and associated complications.- Mallinckrodt + Novoteris LLC

Written by | 2 Apr 2020

Mallinckrodt Plc and Novoteris, LLC, a clinical stage medical device and pharmaceutical developer focused on innovative nitric oxide gas applications, announced that the Therapeutic Products Directorate Of Health… read more.

Synairgen plc initiates Phase II trial of SNG 001 to treat COVID-19 patients .

Written by | 28 Mar 2020

Synairgen plc , the respiratory drug discovery and development company,announces that it has received expedited approvals from the Medicines and Healthcare products Regulatory Agency (MHRA) and Health Research… read more.

EU gives CE mark approval to SARS-CoV-2 test for Coronavirus.- Thermo Fisher

Written by | 28 Mar 2020

Thermo Fisher Scientific Inc announced that it has received the CE mark in the European Union for its diagnostic test to detect nucleic acid from SARS-CoV-2, the virus… read more.

FDA approves Zeposia to treat relapsing forms of multiple sclerosis ,including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.-BMS

Written by | 28 Mar 2020

Bristol-Myers Squibb Company announced that the FDA approved Zeposia (ozanimod) 0.92 mg for the treatment of adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome,… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.